Loading...
By Joe Elia
Edited by Susan Sadoughi, MD, and Richard Saitz, MD, MPH, FACP, DFASAM
When using sulfonylureas as second-line therapy for type 2 diabetes, it's better to continue first-line metformin rather than replacing it, according to a study in The BMJ.
Researchers used U.K. national practice databases to follow outcomes of patients with diabetes starting metformin treatment. Some 25,000 later added a sulfonylurea or switched to it completely from metformin. Each sulfonylurea recipient was matched with a constant metformin user.
After a mean follow-up of roughly 1 year, sulfonylurea use — either as an added or replacement therapy — was associated with increased risks for myocardial infarction (7.8 vs. 6.2 events per 1000 person-years), all-cause mortality (27.3 vs. 21.5), and severe hypoglycemia (5.5 vs. 0.7), relative to metformin monotherapy.
The researchers observe that the MI and mortality risks were driven by switching to sulfonylurea therapy, not by adding a sulfonylurea to metformin. Editorialists agree that adding to metformin seems preferable to replacing it.
Comment
LINK(S):
The BMJ article (Free)
The BMJ editorial (Subscription required)
Background: NEJM Journal Watch General Medicine summary on metformin vs. sulfonylurea monotherapy in chronic kidney disease (Your NEJM Journal Watch subscription required)